Navigation Links
Oncothyreon Reports Third Quarter 2010 Financial Results
Date:11/8/2010

tential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include our expectations regarding future expenses, clinical development activities and the use and adequacy of cash resources.

Forward-looking statements involve risks and uncertainties related to our business and the general economic environment, many beyond our control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements, including the risks associated with the costs and expenses of developing our product candidates, the adequacy of financing and cash reserves on hand, changes in general accounting policies, general economic factors, achievement of the results we anticipate from our clinical trials with our products and our ability to adequately obtain and protect our intellectual property rights.  Although we believe that the forward-looking statements contained herein are reasonable, we can give no assurance that our expectations are correct.  All forward-looking statements are expressly qualified in their entirety by this cautionary statement.  For a detailed description of our risks and uncertainties, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in Canada on SEDAR. Oncothyreon does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof. Additional Information Additional information relating to Oncothyreon can be found on U.S. EDGAR at www.sec.gov and on SEDAR at www.sedar.com. ONCOTHYREON INC. Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
(Unaudited)   Three months ended September 30,'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
2. Oncothyreon announces prioritization plan for development programs
3. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
4. Oncothyreon to present at BIO Investor Forum 2008
5. Oncothyreon announces November 6th webcast of third quarter 2008 financial results and corporate update conference call
6. Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference
7. Oncothyreon reports third quarter 2008 financial results
8. Oncothyreon to present at BIO CEO & Investor Conference 2009
9. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
10. Oncothyreon reports full year and fourth quarter 2008 financial results
11. Oncothyreon to present at Invest Northwest 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... CA (PRWEB) November 21, 2014 Why ... that makes Albert Einstein so instantly recognizable? Why have ... physicist, mathematician, astronomer and author Hilton Ratcliffe seeks out ... have nothing at all to do with science. In ... Harbor Publishing , November 21, 2014), Ratcliffe puts it ...
(Date:11/21/2014)... , Nov. 20, 2014 /CNW/ - Aequus ... to announce that it has closed a brokered ... warrants for approximately C$3.7 million.  Cormark Securities Inc. ... in the Brokered Offering for a syndicate of ... PI Financial Corp. (collectively the "Agents"). Concurrently with ...
(Date:11/18/2014)... FL (PRWEB) November 17, 2014 ... point-of-care diagnostic tests – today announces its third ... and Prevention’s (CDC) Get Smart About Antibiotics Week ... Week is a national campaign designed to highlight ... health departments, and non-profit and for-profit partners to ...
(Date:11/18/2014)... 18, 2014 Alanda Software, a ... Reporting solutions, announced today that a top tier ... Consummate Provider™ solution in both the U.S. and ... SaaS based, Data Quality remediation portal, designed to ... party Providers improve their ability to capture, transmit ...
Breaking Biology Technology:“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2
... of hazardous waste resulting from the nations nuclear weapons ... state called Hanford. Beneath this desert landscape about ... of tons of chemicals are captured within the stratified ... flow paths. These paths create uncertainties about where ...
... the National Nanotechnology Initiative has just been released by ... of the National Science and Technology Councils Committee on ... (NNCO). The 2007 NNI Strategic Plan describes ... ensure that the United States derives growing economic benefits ...
... Pharmos Corporation,(Nasdaq: PARS ) announced today that ... placement of its 10% Convertible Debentures due November ... principal amount of the,Debentures, at par, and received ... purchasers consisted of certain existing investors in the ...
Cached Biology Technology:Where does stored nuclear waste go? 2National Nanotechnology Initiative releases new strategic plan 2National Nanotechnology Initiative releases new strategic plan 3Pharmos Corporation Completes Initial Closing of Private Placement 2
(Date:11/6/2014)... 2014 - Insilico Medicine, Inc, a Baltimore-based bioinformatics ... related diseases announced a research collaboration with the ... Oncology, Inc (OTC: CSBR). , "There are many ... but Champions Oncology,s TumorGraft technology is unique in ... regimen experimentally generating vast amounts of valuable data. ...
(Date:11/5/2014)... in their ability to identify scents and odors. ... perceptual evaluation of odors, with women outperforming men on ... differences in olfactory detection may play a role in ... perception of smell, which is naturally linked to associated ... suggested to be cognitive or emotional, rather than perceptual. ...
(Date:11/4/2014)... Medicine announced today that it is a Grand ... Bill & Melinda Gates Foundation. Laura Goetzl, ... Sciences; and Vice Chair of Research and Academic ... pursue an innovative global health and development research ... Neurodevelopment.", Grand Challenges Explorations (GCE) funds individuals worldwide ...
Breaking Biology News(10 mins):Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2The female nose always knows: Do women have more olfactory neurons? 2Temple University School of Medicine receives Grand Challenges Explorations grant 2
... RIVERSIDE, Calif. Four researchers at the University of California, ... the Advancement of Science ( AAAS ). Including this year,s ... have been recognized with AAAS Fellow distinction is 194. ... members by their peers. This year AAAS gave this honor ...
... risk of attack has led to the development of ... larval stage. One caterpillar may look like a stick, ... may have its advantages, University of Florida researchers uncovered ... another strategy previously best-known in adult butterflies: mimicry. ...
... , The Ontario Genomics Institute (OGI) has awarded two ... leading-edge technologies to better aid the work of Ontario ... Applied Genomics (TCAG), part of The Hospital for Sick ... and Technology Innovation Centre, and StemCore Laboratories based at ...
Cached Biology News:4 UC Riverside researchers receive national recognition 2Caterpillars mimic one another for survival 2Caterpillars mimic one another for survival 32 research facilities awarded technology seeding grants 2
Mouse monoclonal antibody raised against a full length recombinant YARS. NCBI Entrez Gene ID = YARS...
... DS-L2 imaging controller is a successor of ... allows users to comfortably observe, record and ... features an 8.4 inch LCD (XGA) monitor ... Nikon cameras including the DS-Fi1 , DS-5Mc ...
... NovaTaq DNA Polymerase is a premium ... polymerase. This thermostable enzyme is suitable for ... ensure the highest purity and reproducible performance, ... variety of quality control assays. NovaTaq DNA ...
Mouse polyclonal antibody raised against a partial recombinant TSEN2. NCBI Entrez Gene ID = 80746...
Biology Products: